High-dose transdermal E2. Cross-over design with 2 weeks on E2, 2 week washout, and 2 weeks on placebo
8
Therapeutic threshold for levodopa.
All but one participant had levodopa-induced dyskinesia at start of study. After 10 days of E2 treatment a significant reduction was observed in the anti-parkinsonian threshold dose of intravenous levodopa without significantly worsening dyskinesias.
UPDRS, timed tapping score, Hamilton Depression Scale, patient self-report.
“On” and “off” times, and motor score on the UPDRS improved with estrogen.
The Parkinson Study Group Poetry I Investigators [37]
CEE versus Placebo for 8 weeks
23
Primary outcome was ability to complete the trial. Other outcome measures included adverse events, UPDRS, “on” time, dyskinesia ratings, and neuropsychological functioning.
The estrogen group showed a trend for improvement on the total and motor UPDRS scores.